Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologicexperienced patients

被引：0
|
作者：
Dignass, A. [1 ]
Regueiro, M. [2 ]
Colombel, J. F. [3 ]
Jain, A. [4 ]
Canavan, J. B. [4 ]
Wu, H. [4 ]
Lawlor, G. [4 ]
Osterman, M. T. [4 ]
Vermeire, S. [5 ]
Rubin, D. T. [6 ]
机构：
[1] Goethe Univ, Med, Agaples Markus Hosp, Frankfurt, Germany
[2] Cleveland Clin, Digest Dis & Surg Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[4] Bristol Myers Squibb, Clin Res, Princeton, NJ USA
[5] Univ Hosp Leuven, Chron Dis & Metab, Leuven, Belgium
[6] Univ Chicago, Med Inflammatory Bowel Dis, Gastroenterol, Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP43
引用
收藏
页码：I110 / I111
页数：2
相关论文
共 50 条
  • [1] Extended induction in the True North open-label extension study: Ozanimod efficacy in biologic-naive and biologic-experienced patients
    Dignass, A.
    Sparrow, M.
    Regueiro, M.
    Colombel, J-F
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Vermeire, S.
    Rubin, D. T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 120 - 121
  • [2] Endoscopic and Clinical Efficacy Demonstrated with Oral Ozanimod in Active Crohn's Disease in Biologic-Naive and Biologic Experienced Patients
    Brian, Feagan
    William, Sandborn
    Silvio, Danese
    Geert, D'Haens
    Barrett, Levesque
    Brett, Skolnick
    David, Paul
    Richard, Aranda
    Allan, Olson
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S3 - S3
  • [3] Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
    Sands, B. E.
    Dignass, A.
    Irving, P.
    Chiorean, M.
    Long, M.
    Eren, D.
    Ahmad, H. A.
    Osterman, M. T.
    Petersen, A.
    Elegbe, A.
    Ritter, T.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I339 - I340
  • [4] Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
    Sands, B. E.
    Dignass, A.
    Irving, P.
    Chiorean, M.
    Long, M.
    Eren, D.
    Ahmad, H. A.
    Osterman, M. T.
    Petersen, A.
    Elegbe, A.
    Ritter, T.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I339 - I340
  • [5] Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North
    Sands, Bruce E.
    Dignass, Axel
    Irving, Peter
    Chiorean, Michael
    Long, Millie
    Ahmad, Harris A.
    Osterman, Mark
    Petersen, AnnKatrin
    Elegbe, Ayanbola
    Ritter, Timothy E.
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S512 - S513
  • [6] ANALYSIS EFFICACY OF ABATACEPT TREATMENT IN BIOLOGIC-NAIVE AND BIOLOGIC-EXPERIENCED PATIENTS.
    Borisova, M.
    Lukina, G.
    Yakov, S.
    Luchikhina, E.
    Karateev, D.
    Novikov, A.
    Aleksandrova, E.
    Aronova, E.
    Glukhova, S.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1300 - 1300
  • [7] No Impact of Seronegativity on the Efficacy of a Biosimilar Rituximab in Biologic-naive Patients with Active Rheumatoid Arthritis
    Jamshid, Nedumooli Pottammal
    Ravindran, Vinod
    INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (01) : 77 - 78
  • [8] EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT
    Rubin, David T.
    Colombel, Jean Frederic
    Chiorean, Michael V.
    Ghosh, Subrata
    Jain, Anjali
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S1102 - S1102
  • [9] Extended induction in the True North open-label extension study: clinical outcomes of ∼2 years of ozanimod treatment
    Vermeire, S.
    Colombel, J. F.
    Chiorean, M. V.
    Ghosh, S.
    Jain, A.
    Lawlor, G.
    Osterman, M. T.
    Wu, H.
    Canavan, J. B.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 903 - 904
  • [10] Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study
    William, Sandborn
    Geert, D'Haens
    Doug, Wolf
    Stephen, Hanauer
    Igor, Jovanovic
    Subrata, Ghosh
    AnnKatrin, Petersen
    Steven, Hua
    Hwan, Lee Ji
    Lorna, Charles
    Keith, Usiskin
    Silvio, Danese
    Brian, Feagan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S6 - S7
12345